Literature DB >> 20546962

Hemostasis and thrombosis in patients with liver disease: the ups and downs.

Ton Lisman1, Stephen H Caldwell, Andrew K Burroughs, Patrick G Northup, Marco Senzolo, R Todd Stravitz, Armando Tripodi, James F Trotter, Dominique-Charles Valla, Robert J Porte.   

Abstract

Patients with chronic or acute liver failure frequently show profound abnormalities in their hemostatic system. Whereas routine laboratory tests of hemostasis suggest these hemostatic alterations result in a bleeding diathesis, accumulating evidence from both clinical and laboratory studies suggest that the situation is more complex. The average patient with liver failure may be in hemostatic balance despite prolonged routine coagulation tests, since both pro- and antihemostatic factors are affected, the latter of which are not well reflected in routine coagulation testing. However, this balance may easily tip towards a hypo- or hypercoagulable situation. Indeed, patients with liver disease may encounter both hemostasis-related bleeding episodes as well as thrombotic events. During the 3rd International Symposium on Coagulopathy and Liver disease, held in Groningen, The Netherlands (18-19 September 2009), a multidisciplinary panel of experts critically reviewed the current data concerning pathophysiology and clinical consequences of hemostatic disorders in patients with liver disease. Highlights of this symposium are summarized in this review. Copyright 2010. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20546962     DOI: 10.1016/j.jhep.2010.01.042

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  68 in total

Review 1.  Acute variceal bleeding: risk stratification and management (including TIPS).

Authors:  Virginia Hernández-Gea; Claudia Berbel; Anna Baiges; Juan C García-Pagán
Journal:  Hepatol Int       Date:  2017-06-20       Impact factor: 6.047

2.  Safety of Ascitic Paracentesis in Patients with Budd-Chiari Syndrome on Oral Anticoagulation and Elevated International Normalized Ratio.

Authors:  Harshad Devarbhavi; Arvind R Murali
Journal:  J Clin Exp Hepatol       Date:  2015-09-01

Review 3.  Coagulation in liver toxicity and disease: role of hepatocyte tissue factor.

Authors:  Anna K Kopec; James P Luyendyk
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

4.  Changing common sense: Anti-platelet/coagulation therapy against cirrhosis.

Authors:  Yoshihiro Ikura; Tatsuya Osuga
Journal:  World J Hepatol       Date:  2015-07-08

5.  Venous thromboembolism in patients with liver diseases.

Authors:  Valerio De Stefano; Elena Rossi
Journal:  Intern Emerg Med       Date:  2015-03-13       Impact factor: 3.397

6.  Von Willebrand factor deficiency reduces liver fibrosis in mice.

Authors:  Nikita Joshi; Anna K Kopec; Jessica L Ray; Holly Cline-Fedewa; Dafna J Groeneveld; Ton Lisman; James P Luyendyk
Journal:  Toxicol Appl Pharmacol       Date:  2017-05-17       Impact factor: 4.219

7.  A Miniaturized Hemoretractometer for Blood Clot Retraction Testing.

Authors:  Zida Li; Xiang Li; Brendan McCracken; Yue Shao; Kevin Ward; Jianping Fu
Journal:  Small       Date:  2016-06-01       Impact factor: 13.281

8.  Venous Thromboembolism Prophylaxis in Liver Surgery.

Authors:  Thomas A Aloia; William H Geerts; Bryan M Clary; Ryan W Day; Alan W Hemming; Luiz Carneiro D'Albuquerque; Charles M Vollmer; Jean-Nicolas Vauthey; Giles J Toogood
Journal:  J Gastrointest Surg       Date:  2016-01       Impact factor: 3.452

9.  Management of coagulopathy in liver disease.

Authors:  Stephen H Caldwell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

Review 10.  Algorithms for managing coagulation disorders in liver disease.

Authors:  R Todd Stravitz
Journal:  Hepatol Int       Date:  2018-07-31       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.